Immunohistochemical detection of mutant p53 protein in small-cell lung cancer: Relationship to treatment outcome

Lung Cancer

Volumn 29, Issue 1, 2000, Pages 23-31

  Gemba, Kenichi ^a   Ueoka, Hiroshi ^a   Kiura, Katsuyuki ^a   Tabata, Masahiro ^a   Harada, Mine ^a  

^a OKAYAMA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

Chemotherapy; Immunohistochemistry; Lung cancer; Mutant p53 protein; p53 Gene; Prognostic factor; Small cell lung cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; METHOTREXATE; NIMUSTINE; PROTEIN P53; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; FEMALE; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TUMOR BIOPSY;

EID: 0034125143     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(00)00098-2     Document Type: Article

References (30)

1. Jenkins J.R., Rudge K., Chumakov P., Currie G.A. The cellular oncogene p53 can be activated by mutagenesis. Nature. 317:1985;816-818.
2. Lane D.P. Cancer: p53, guardian of the genome. Nature. 358:1992;15-16.
3. Mercer W.E., Shields M.T., Amin M., Sauve G.J., Appella E., Romano J.W. et al. Negative growth regulation in a glioblastoma tumor cell line that conditionally expresses human wild-type p53. Proc. Natl. Acad. Sci. U.S.A. 87:1990;6166-6170.
4. Baker S.J., Markowitz S., Fearon E.R., Wilson J.K., Vogelstein B. Suppression of human colorectal carcinoma cell growth by wild-type p53. Science. 249:1990;912-915.
5. MacLaren R., Kuzu I., Dunnill M., Harris A., Lane D., Gatter K.C. The relationship of p53 immunostaining to survival in carcinoma of the lung. Br. J. Cancer. 66:1992;735-738.
6. Gannon J.V., Graves R., Iggo R., Lane D.P. Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J. 9:1990;1595-1602.
7. Baker S.J., Preisinger A.C., Jessup J.M., Paraskeva C., Markowitz S., Wilson J.K. et al. p53 Gene mutation occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. Cancer Res. 50:1990;7717-7722.
8. Iwaya K., Tsuda H., Hiraide H., Tamaki K., Tamakuma S., Fukutomi T. et al. Nuclear p53 immunoreaction associated with poor prognosis of breast cancer. Jpn. J. Cancer Res. 82:1991;835-840.
9. Quinlan D.C., Davidson A.G., Summers C.L., Warden H.E., Doshi H.M. Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. Cancer Res. 52:1992;4828-4831.
10. Horio Y., Takahashi T., Kuroishi T., Hibi K., Suyama M., Niimi T. et al. Prognostic significance of p53 mutation and 3p deletions in primary resected non-small cell lung cancer. Cancer Res. 53:1993;1-4.
11. Mitsudomi T., Oyama T., Kusano T., Osaki T., Nakanishi R., Shirakusa T. Mutation of the p53 gene as a predictor of poor prognosis in patients with non-small cell lung cancer. J. Natl. Cancer Inst. 85:1993;2018-2023.
12. Takahashi T., Takahashi T., Suzuki H., Hida T., Sekido Y., Ueda R. et al. The p53 gene is very frequently mutated in small-cell lung cancer with a distinct nucleotide substitution pattern. Oncogene. 6:1991;1775-1778.
13. Sameshima Y., Matsuno Y., Hirohasi S., Shimosato Y., Mizoguchi H., Yokota J. et al. Alterations of the p53 gene are common and critical events for the maintenance of malignant phenotypes in small-cell lung carcinoma. Oncogene. 7:1992;451-457.
14. Ohnoshi T., Hiraki S., Kawahara S., Yamashita H., Yonei T., Ishikawa J. et al. Randomized trial comparing chemotherapy alone and chemotherapy and chest irradiation in limited stage small cell lung cancer: a preliminary report. Jpn. J. Clin. Oncol. 16:1986;271-277.
15. Ohnoshi T., Hiraki S., Ueoka H., Kiura K., Kamei H., Horiguchi T. et al. Pilot study of cyclophosphamide-doxorubicin-vincristine-cisplatin-etoposide hybrid chemotherapy in small cell lung cancer. Cancer. 72:1993;1597-1601.
16. Ueoka H., Kiura K., Tabata M., Kamei H., Gemba K., Sakae K. et al. A randomized trialof hybrid administration of cyclophosphamide, doxorubicin, and vincristine (CAV)/cisplatin and etoposide (PVP) versus sequential administration of CAV-PVP for the treatment of patients with small cell lung carcinoma. Cancer. 83:1998;283-290.
17. Suzuki S., Matsubara N., Kumano N., Nakai Y., Saito J., Sugawara S. et al. Effect of IFN-α on retinoblastoma gene expression in human small cell lung cancer cell lines. Proc. Jpn. Cancer Res. 51:1992;151.
18. Kaplan E.L., Meier P. Nonparametric estimation for incomplete observations. J. Am. Stat. Assoc. 53:1958;457-481.
19. Gehan E.A. A generalized Wilcoxon test for comparing arbitrarily single-censored samples. Biometrika. 52:1965;203-204.
20. Cox D.R. Regression models and life tables. J. R. Stat. Soc. (B). 34:1972;187-220.
21. Sphopland D.W., Eyre H.J., Pechacek T.F. Smoking-attributable cancer mortality in 1991: is lung cancer now the leading cause of death among smokers in the United States? J. Natl. Cancer Inst. 83:1991;1142-1148.
22. Suzuki H., Takahashi T., Kuroishi T., Suyama M., Ariyoshi Y., Takahashi T. et al. p53 Mutations in non-small cell lung cancer in Japan: association between mutations and smoking. Cancer Res. 52:1992;734-736.
23. Lohmann D., Puts B., Reich U., Bohm J., Prauer H., Hofler H. Mutational spectrum of the p53 gene in human small-cell lung cancer and relationship to clinicopathological data. Am. J. Pathol. 142:1993;907-915.
24. Pastorino U., Andreola S., Tagliabue E., Pezzella F., Incarbone M., Sozzi G. et al. Immunocytochemical markers in stage I lung cancer: relevance to prognosis. J. Clin. Oncol. 15:1997;2858-2865.
25. Seiffer E.J., Ihde D.C. Therapy of small cell lung cancer: a perspective on 2 decades of clinical research. Sem. Oncol. 15:1988;278-279.
26. Chin K.W., Ueda K., Pastan I., Gottesman M.M. Modulation of activity of the promoter of the human MDR1 gene by ras and p53. Science. 255:1992;459-462.
27. Lowe S.W., Ruley H.E., Jacks T., Housman D.E. p53-Dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell. 74:1993;957-967.
28. Fujiwara T., Grimm E.G., Mukhopadhyay T., Zhang W., Owen-Schaub L.B., Roth J.A. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res. 54:1994;2287-2291.
29. Segawa Y., Ohnoshi T., Hiraki S., Ueoka H., Kiura K., Kamei H. et al. Immunohistochemical detection of P-glycoprotein and carcinoembryonic antigen in small cell lung cancer: with reference to predictability of response to chemotherapy. Acta. Med. Okayama. 47:1993;181-189.
30. Tabata M., Ohnoshi T., Ueoka H., Kiura K., Kimura I. MDR1 gene expression and treatment outcome in small cell lung cancer: MDR1 gene expression as an independent prognostic factor. Acta. Med. Okayama. 47:1993;243-248.